Stockreport

Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]

Olema Pharmaceuticals, Inc.  (OLMA) 
PDF combinations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) New clinical data for palazestrant (OP-1250) in combination with riboc [Read more]